This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Company Statement: Sanofi and Glenmark Pharmaceuticals sign license agreement on monoclonal antibody for crohn's disease and other chronic autoimmune disorders

( May 16, 2011, 14:15 GMT | Official Statement) -- MLex Summary: Sanofi has announced that its has entered into a licensing agreement with Glenmark Pharmaceuticals to facilitate the development of GBR500, a new monoclonal antibody to treat crohn's disease and other similar disorders. The transaction is subject to the expiry of the waiting period under the Hart Scott Rodino Act.  Sanofi and Glenmark Pharmaceuticals Sign License Agreement on Novel Monoclonal Antibody for Crohn's Disease and Other Chronic Autoimmune Disorders...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login